Tag Archives: Epilepsy

What the Research Says About the Health Benefits and Risks of Marijuana

What the Research Says About the Health Benefits and Risks of Marijuana

What the Research Says About the Health Benefits and Risks of Marijuana

A landmark federal report released in 2017 outlined what’s known about the potential health benefits and risks of marijuana use.

The History of Marijuana in North Carolina

The History of Marijuana in North Carolina

Marijuana has thousands of years of history all across the world and in the United States. In the United States, marijuana has a history of prohibition and legalization both at the state and federal levels. Many southern states are actually taking action to join the fight for legalization. North Carolina is among one of these southern states that is moving forward with marijuana legalization.

Tillis Co-Sponsors Legislation to Expand Research into Medical Benefits of Cannabidiol

RALEIGH, N.C., June 5, 2017 /Weed Wire/ – U.S. Senator Thom Tillis (R-NC) recently co-sponsored the Cannabidiol Research Expansion Act, a bill to support research initiatives on the potential benefits of substances such as cannabidiol (CBD) that are derived from marijuana.

Seizures

Cannabis Derivative Cannabidiol Reduces Seizures in Severe Epilepsy Disorder

NEW YORK, May 24, 2017 /Weed Wire/ – After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency 39 percent for patients with Dravet syndrome—a rare, severe form of epilepsy—in the first large-scale, randomized clinical trial for the compound.

Congressman Perry Introduces Bill to Help Epileptic Children

WASHINGTON, May 1, 2017 /Weed Wire/ – Continuing his fight to help families with children suffering from debilitating forms of epilepsy, Congressman Scott Perry joined with Senator Corey Gardner (R-CO) to reintroduce the Charlotte’s Web Medical Access Act of 2017.

SeeThruEquity RSHO Raúl Elizalde

Study Results: Medical Marijuana, Inc. Subsidiary HempMeds Mexico Announces Release of Study Using Its Real Scientific Hemp Oil-X to Treat Epileptic Children

SAN DIEGO, Calif., March 14, 2017 /Weed Wire/ — Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico is holding a press conference in Mexico City, Mexico, today to reveal the positive results of a recent study conducted by renowned Mexican physician Dr. Saul Garza Morales on the effects of the Company’s Real Scientific Hemp Oil-X™ (RSHO-X™) product in treating children with severe epilepsy.

Peruvian Attitudes Toward Medical Marijuana Shift After Raid on Moms' Lab

Peruvian Attitudes Toward Medical Marijuana Shift After Raid on Moms’ Lab

Peru is a conservative nation with strict drug laws and a politically right-leaning Congress, but when police raided a lab in which mothers made medical marijuana for their sick children, attitudes began to change, according to a March 2, 2017, article by Reuters.

Dad Says Doctor Stopped Seeing His Daughter Due to CBD Oil Use

Dad Says Doctor Stopped Seeing His Daughter Due to CBD Oil Use

A Duke doctor has refused to continue seeing a nine-year-old North Carolina girl because her family gives her cannabidiol oil to cope with a rare illnes. The nine-year-old, Mia Morley, has a medical condition called Lennox Gastaut Syndrome. Her father, Dylan Morley, said Dr. Muhammad Mikati’s decision was based upon the federal status of CBD oil, which is not FDA approved.

Washington State Bill Would Allow Medical Marijuana at Public Schools

Washington State Bill Would Allow Medical Pot at Public Schools

The father of a first-grade student in Aberdeen, Washington, could become the catalyst for a change in state law that would allow CBD oil at public schools. River Barclay, 7, needs CBD oil to manage a rare form of epilepsy, but state law will not allow her father to go to the school to administer the dose because medical marijuana is illegal on school property.

GWPH Riding High: Stock Rises on Clinical Trial's Positive Results

GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results

On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.

Third win for cannabis drug in epilepsy sends GW to record high

Third Win for Cannabis Drug in Epilepsy Sends GW to Record High

An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain’s GW Pharmaceuticals to a record high on Monday.

Georgia’s Medical Marijuana Law Just Turned One Year Old

Georgia’s Medical Marijuana Law Just Turned One Year Old

The phones at the Georgia Department of Public Health no longer ring off the hook with people calling to find doctors or asking questions about how the state’s medical marijuana registry works.

North Carolina

New North Carolina Bill Seeks Legalization of Medical Marijuana

A new bill in the North Carolina legislature seeks to legalize medical marijuana. House Bill 983, filed about a month ago, is an update of previously failed legislative attempts to legalize medical marijuana in the state. It would allow medical marijuana use by “patients with terminal or chronic illnesses.” Currently, the state only allows CBD oil for epilepsy.

Insys Therapeutics

Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients

PHOENIX, May 24, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.

Epidiolex in Utah

Epidiolex in Utah: Decrease in Seizure Frequency and Severity

In September 2014, The University of Utah’s Division of Pediatric Neurology and Primary Children’s Medical Center started the first of three clinical trials on the efficacy of Epidiolex, a nonpsychoactive cannabidiol-based drug from GW Pharmaceuticals (NASDAQ: GWPH).

GWPH Phase 3 Results

GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex

LONDON, April 11, 2016 /Weed Wire/ — GW Pharmaceuticals plc today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy.

GW Pharma

GW Pharma Reports Positive Results and Stock More than Doubles by Mid-Day

On March 14, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for the first pivotal Phase 3 study of Epidiolex, a CBD-based medicine, in treating Dravet syndrome, a severe form of pediatric epilepsy.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)

LONDON, March 14, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome.

Nebraska

Nebraska Takes Second Look at Medical Marijuana

On March 3, 2016, Shelley Gillen, a mother whose 13-year-old son suffers from severe epileptic seizures, met with Nebraska Sen. Sue Crawford in an attempt to convince the senator to support LB 643, a bill introduced by Sen. Tommy Garrett that would establish the Cannabis Compassion and Care Act.


Page 1 of 212
Top